Skip to main content
MBI logo

MBI — Investor Relations & Filings

Ticker · 1783 ISIN · TW0001783009 TW Manufacturing
Open in API
Filings indexed 1,692 across all filing types
Latest filing 2025-02-05 Regulatory Filings
Country TW Taiwan
Listing TW 1783

About MBI

www.mbi.com.tw

Maxigen Biotech Inc. (MBI) is a medical device manufacturer specializing in the research, development, and production of biopolymer-based solutions, primarily focusing on collagen matrix and hyaluronic acid technologies. The company provides a comprehensive range of medical devices across multiple clinical disciplines, including orthopedics, aesthetics, ophthalmology, and wound care. Key products include hyaluronic acid intra-articular injections, dermal fillers, ophthalmic viscoelastics, collagen wound dressings, dental membranes, and synthetic bone grafts. In addition to its proprietary brands, MBI offers global OEM/ODM and customization services. The company adheres to international quality standards, holding certifications such as CE, FDA, NMPA, and MDSAP. MBI leverages its expertise in biopolymer science to deliver innovative medical and skincare products to international markets.

Recent filings

Filing Released Lang Actions
114年1月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a listed company, 和康生, reporting on the status of fund loans and endorsement guarantees for the current and previous month, with amounts all zero. It contains no detailed financial statements, no management discussion, no earnings highlights, no meeting materials, and no legal or regulatory narrative. The document is very short (602 characters) and purely factual, typical of a regulatory compliance disclosure or routine financial status update. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a report publication announcement since it contains actual data, but the data is minimal and routine. Given the nature and brevity, this fits best under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory disclosures that do not fit other categories.
2025-02-05 Chinese
114年1月營業收入
Fund Information / Factsheet Classification · 95% confidence The document is a brief financial summary showing monthly and cumulative net operating revenue figures for a company, with percentage changes compared to the previous year. It includes notes on accounting standards and reporting practices but does not contain detailed financial statements or comprehensive analysis. The document length is only 765 characters, indicating it is a short summary rather than a full report. There is no indication that this is an announcement of a report publication or a certification. Given the brief nature and content, this fits best as a Fund Information / Factsheet (FS), which is a brief summary of key company financials and market info.
2025-02-05 Chinese
員工認股權憑證執行情形
Capital/Financing Update Classification · 95% confidence The document is a regulatory disclosure from a listed company (和康生) regarding the issuance of employee stock options or warrants. It includes details such as the number of shares issued, subscription prices, subscription period, purpose of issuance, potential dilution impact, and effects on shareholder equity. The content focuses on capital raising through employee stock options and related capital structure changes. The document length is short (1240 characters) and it is not a report or announcement of a report publication but a specific update on financing activity. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-01-15 Chinese
員工認股權憑證執行情形
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the issuance of employee stock options (認股權憑證) by the company 和康生 (code 1783). It includes specifics such as the number of shares issued, subscription prices, subscription period, purpose of issuance, potential dilution impact, and effects on shareholder equity. The content focuses on capital structure changes related to employee stock options and their impact on shareholders. There is no indication that this is a full financial report, audit, or earnings release. The document is not a brief announcement of a report publication or a certification. Given the detailed nature of the capital issuance and its impact, this fits best under the category of Capital/Financing Update (CAP). The document length is short but contains substantive data about the capital issuance, not just a notice or link to a report.
2025-01-15 Chinese
113年12月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a financial disclosure from a listed company, 和康生, providing data on fund lending balances and endorsement guarantees for the current and previous months, including limits and cumulative amounts. The content is brief (606 characters) and consists mainly of tabular financial data related to internal fund lending and guarantees, without detailed financial statements or analysis. It does not present a full financial report, nor does it announce a report publication or voting results. The document is a regulatory disclosure of financial information but does not fit into categories like Annual Report, Interim Report, or Earnings Release. Given the nature and brevity, it best fits under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory disclosures that do not fit other categories.
2025-01-08 Chinese
113年12月營業收入
Regulatory Filings Classification · 90% confidence The document is a summary revenue report from a listed company, showing monthly and cumulative revenue figures with percentage changes compared to the previous year. It includes notes on accounting standards (IFRS) and reporting practices. The document is short (766 characters) and primarily provides financial summary data without detailed financial statements or management discussion. It does not appear to be a full annual or interim report, nor an earnings release with key highlights. It is more of a regulatory financial summary or announcement of financial data. Given the short length and nature, it fits best under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory financial disclosures that do not fit other categories.
2025-01-08 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.